SLSharne Limb

Sharne Limb

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sharne Limb has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The co-design, development, and preliminary evaluation of a comprehensive breast cancer risk report incorporating polygenic risk information

    by Mia N. Hanley, Rebecca Purvis, Sharne Limb, Sibel Saya, Adrian Bickerstaffe, Jack Wheeler, Yuhan Shen, Matilda Hilton, Minchen Dai, Edbert Liu, et al.

    The clinical implementation of polygenic risk scores (PGS) in comprehensive cancer risk assessments is imminent. The successful implementation relies on clear communication to consumers to facilitate understanding of personalised risk information and motivate cancer prevention behaviours. Development of provider- and consumer-friendly resources to aid communication and understanding of PGS results is a critical implementation task. This study aimed to produce an acceptable report for delivering comprehensive, PGS-informed breast cancer risk assessments in research and clinical settings. A two-phase, multi-methods research program was conducted, focusing on co-design with a broad group of interest holders to gather preferences and feedback on the content, layout and visual tools of a risk report. Phase 1 involved a literature review, a quantitative survey with consumers and qualitative interviews with consumers and medical practitioners to generate an initial prototype report. Phase 2 involved qualitative interviews with genetic counsellors to seek feedback about the prototype and refine it into a final version. The report was operationalised as a web-based application that generates personalised versions in PDF. The evidence-based, interest-holder-informed comprehensive breast cancer risk report produced is highly usable, able to support ongoing clinical implementation research on PGS across cancer use-cases and contexts. Future work should explore consumer evaluation of the report and the feasibility of interactive and digital delivery mechanisms.

  • Open Access

    The co-design, development, and preliminary evaluation of a comprehensive breast cancer risk report incorporating polygenic risk information

    by Laura Forrest, Mia Hanley, Rebecca Purvis, Sharne Limb, Sibel Saya, Adrian Bickerstaffe, Jack Wheeler, Yuhan Shen, Matilda Hilton, Minchen Dai, et al.

    The clinical implementation of polygenic risk scores (PGS) in comprehensive cancer risk assessments is imminent. The successful implementation relies on clear communication to consumers to facilitate understanding of personalised risk information and motivate cancer prevention behaviours. Development of provider- and consumer-friendly resources to aid communication and understanding of PGS results is a critical implementation task. This study aimed to produce an acceptable report for delivering comprehensive, PGS-informed breast cancer risk assessments in research and clinical settings. A two-phase, multi-methods research program was conducted, focusing on co-design with a broad group of interest holders to gather preferences and feedback on the content, layout, and visual tools of a risk report. Phase 1 involved a literature review, quantitative survey with consumers, and qualitative interviews with consumers and medical practitioners to generate an initial prototype report. Phase 2 involved qualitative interviews with genetic counsellors to seek feedback about the prototype and refine it into a final version. The report was operationalised as a web-based application that generates personalised versions in PDF. The evidence-based, interest-holder informed comprehensive breast cancer risk report produced is highly useable, able to support ongoing clinical implementation research on PGS across cancer use-cases and contexts. Future work should explore consumer evaluation of the report and feasibility of interactive and digital delivery mechanisms.

  • Open Access

    TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members

    by Rachel Delahunty, Linh Nguyen, Stuart Craig, Belinda Creighton, Dinuka Ariyaratne, Dale W. Garsed, Elizabeth Christie, Sian Fereday, Lesley Andrews, Alexandra Lewis, et al.

    PURPOSE: Tubo-ovarian cancer (TOC) is a sentinel cancer for BRCA1 and BRCA2 pathogenic variants (PVs). Identification of a PV in the first member of a family at increased genetic risk (the proband) provides opportunities for cancer prevention in other at-risk family members. Although Australian testing rates are now high, PVs in patients with TOC whose diagnosis predated revised testing guidelines might have been missed. We assessed the feasibility of detecting PVs in this population to enable genetic risk reduction in relatives. PATIENTS AND METHODS: In this pilot study, deceased probands were ascertained from research cohort studies, identification by a relative, and gynecologic oncology clinics. DNA was extracted from archival tissue or stored blood for panel sequencing of 10 risk-associated genes. Testing of deceased probands ascertained through clinic records was performed with a consent waiver. RESULTS: We identified 85 PVs in 84 of 787 (11%) probands. Familial contacts of 39 of 60 (65%) deceased probands with an identified recipient (60 of 84; 71%) have received a written notification of results, with follow-up verbal contact made in 85% (33 of 39). A minority of families (n = 4) were already aware of the PV. For many (29 of 33; 88%), the genetic result provided new information and referral to a genetic service was accepted in most cases (66%; 19 of 29). Those who declined referral (4 of 29) were all male next of kin whose family member had died more than 10 years before. CONCLUSION: We overcame ethical and logistic challenges to demonstrate that retrospective genetic testing to identify PVs in previously untested deceased probands with TOC is feasible. Understanding reasons for a family member's decision to accept or decline a referral will be important for guiding future TRACEBACK projects.